TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective cesarean planned under spinal anesthesia~* Singleton pregnancy~* American Society of Anesthesiologists (ASA) classification score of 2 (or less)~* Gestational age of at least 37 weeks~* Intention to breastfeed infant~Exclusion Criteria:~* Contraindications to neuraxial blockade (such as clinically relevant coagulopathy, recent anticoagulant use, patient refusal, or localized skin infection overlying the site of needle entry)~* Anatomical abnormalities contraindicating spinal or QLB placement~* Received/Conversion to general anesthesia~* Received supplemental parenteral anesthesia (sedation) for any reason (e.g. unanticipated prolonged surgical procedure)~* History of chronic pain~* History of chronic opioid use/abuse~* History of Subutex, methadone, other maintenance therapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- ITM + Sham QLB (Type: SHAM_COMPARATOR): Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
- ITM + Bupivacaine QLB (Type: EXPERIMENTAL): Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultra-low-dose CACS in a Large Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred for a non-contrast enhanced CT scan for CAC scoring~* Male and Female subjects ≥18 years of age,~* Written informed consent~Exclusion Criteria:~* Pregnancy or breast-feeding~* CACS of 0 after inclusion of 50 patients with CACS 0 (as assessed visually after the first CT scan, prior to performing the 3 additional study scans)~* History of coronary artery stenting, coronary artery bypass grafting, of implantation of cardiac devices (e.g. valve prosthesis, pacemaker, implantable cardioverter defibrillator etc.)~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard and ultra-low-dose CAC scoring (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Continous Lumbar Plexus Block in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Paediatric patients undergoing elective unilateral open hip and femoral surgery requiring general anaesthesia with intubation at the University Hospital - Inselspital in Bern.~* American Society of Anesthesiologist (ASA) physical status 1-3~* 8-16 year old with legal guardians providing written informed consent.~Exclusion Criteria:~* Obesity (BMI 30 kg/m2)~* Infeasibility to use a PCA pump~* Known or suspected infection of the skin at the site of needle puncture area~* Known allergy to ropivacaine~* Severe spine deformity~* Neuromuscular disease~* Coagulopathy.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
- Control group (Type: NO_INTERVENTION): Patients in the control group (and in the active treatment group) will receive an opioid-based analgesia with a hydromorphone-patient controlled analgesia (PCA) depending on their analgesic demand

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CES in the Elderly With Generalized Anxiety Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 60 to 85 years old~* Anxiety disorder confirmed by Mini-international neuropsychiatric interview (MINI)~* HAM-A score greater than 17 points~* HAM-D score lower than 17 points~* Mini-mental state examination score of 24 or more~* No psychiatric medication adjustment within 3 months.~Exclusion Criteria:~* Comorbid with another axis I psychiatric disorder, like schizophrenia, substance use disorder or other major mental illness screened by Mini-international neuropsychiatric interview (MINI)~* Contraindications for CES~* Implanted brain medical devices or mental in the head~* History of seizures~* History of intracranial neoplasm or surgery~* Severe head injuries~* Cerebrovascular diseases~* Arrhythmia or with pacemaker implantation~* Used to receive brain stimulation therapy.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Received CES intervention (Type: EXPERIMENTAL): CES with the frequency of 0.5 Hertz; current of 100\~600micro-ampere, for 60 minutes, everyday for 6 weeks, total 42 sessions intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: COPD Patients Diagnosed With GERD,COPD Exacerbations After Treatment With High Dose PPI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of COPD~* forced expiratory volume/forced vital capacity ratio (FEV1/FVC) of \< 70% on pulmonary function testing~* age \> 40 years~* \>20 pack year history of smoking~Exclusion Criteria:~* presence of the following disorders: respiratory disorders other than COPD, known esophageal disease such as cancer, achalasia, stricture, active peptic ulcer disease, Zollinger-Ellison syndrome, mastocytosis, scleroderma, or current abuse of alcohol defined as greater than three alcoholic drinks per day.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- esomeprazole (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with spontaneous aneurysmal subarachnoid hemorrhage (SAH) defined according to Hunt and Hess scale grade HH5~* Requiring mechanical ventilation in the ICU at the time of enrolment~* Enteral nutrition (EN) in the ICU at time of enrolment~  * If enrolment on day 3 of ICU stay, EN equal to or larger than 80% of total calories in case of supplementary parenteral nutrition (PN) with anticipated 100% EN as of day 4 to 8 of ICU stay~ * If enrolment on day 4 of ICU stay, 100% EN planned for at least 5 days from the time of enrolment~* Patients expected to stay in the ICU for at least 5 days following enrolment~* Age 18 - 75 years~* Glycemic control with intravenous insulin therapy to maintain a target glucose range between 110 mg/dL and 150 mg/dL (6.1 and 8.3 mmol/l)~* Informed consent according to local regulations for decisionally impaired subjects~Exclusion Criteria:~* Patients with septic shock at time of enrolment~* Participation in a clinical trial with any investigational product within 4 weeks before study~* Patients requiring a fibre free diet~* Total or supplementary parenteral nutrition (\> 20% of total calories)~* Known or suspected intolerance or allergy to any component of the study product(s), e.g. galactosemia~* Gastrectomy~* Postpyloric nutrition~* Any clinical condition not allowing enteral nutrition (e.g. emesis, severe reflux, severe diarrhea)~* Known severe heart failure (NYHA class 4)~* Liver insufficiency / failure (male: ALAT \> 150 U/l; female: ALAT \> 120 U/l)~* Acute kidney failure (blood creatinine \> 2.5 mg/dl)~* Body Mass Index \< 18 or \> 35 kg/m²~* Known or suspicion of drug abuse~* Pregnant or breast feeding women~* Patients with diabetes mellitus type I~Exclusion After Enrolment (Withdrawal of Subjects)~* Start of PN with more than 20% of total given energy amount/ day~* Insulin infusion stopped unexpectedly for \> 12h for non-nutritional reasons~* Discharge from ICU~* Intolerable AEs~* Major protocol violation~* Withdrawal of informed consent~* Discontinuation of study treatment for other reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Diben 1.5 kcal HP (Type: OTHER): Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
- Fresubin HP Energy Fibre (1.5 kcal) (Type: OTHER): Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female age ≤ 37 years~* BMI 18-29 kg/m2~* Regular cycle (25-35 days)~* Standard indication for IVF~* No major uterine abnormalities~* Written informed consent~Exclusion Criteria:~* Indication for IVF male factor with a total motile sperm count \< 20x106~* ICSI or andrological indication~* Known abnormal (male or female) karyotype~* Oocyte donation~* One previous IVF treatment not resulting in embryo transfer~* History of recurrent abortion~* Medical contra indication for pregnancy or IVF treatment~* Relevant systemic disease~* Active substance abuse

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
- 2 (Type: EXPERIMENTAL): Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Three Exercise Programs in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Regular use of medication for PD;~* Age greater than or equal to 60 years;~* Stage 2, 2.5 or 3 according to the modified Hoehn and Yahr classification;~* Signed informed consent.~Exclusion Criteria:~* neurodegenerative diseases other than Parkinson disease; dementia; muscle diseases that preclude the practice of physical activity; chronic uncontrolled disease (hypertension, diabetes mellitus, chronic pain); unstable cardiovascular disease (acute heart failure, myocardial recent infarction, unstable angina and uncontrolled arrhythmia); using alcohol and other toxic substances; contraindications for performing exercise according the criteria of the American College of Sports Medicine; to practice or have practiced physical exercise program in the last six months; to participate or have participated in regular resistance training (eg, 2-3 times per week) in the previous 12 months.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Functional Training (Type: EXPERIMENTAL): Functional exercise training program
- Stationary Bike (Type: EXPERIMENTAL): Stationary bike training program
- Exergaming (Type: EXPERIMENTAL): Virtual Reality Exposure Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* CKD (stage V) on outpatient hemodialysis therapy for \>= 3 months;~* CKD-related anemia treated with epoetin alfa iv 3x/week for \>= 3 months;~* average hemoglobin (Hb) 10-12 g/dL over last 3 months.~Exclusion Criteria:~* failed renal transplant within 12 months prior to screening;~* poorly controlled hypertension;~* previous treatment with Mircera.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- methoxy polyethylene glycol-epoetin beta (Type: EXPERIMENTAL): 120-360 micrograms (iv) monthly, starting dose
- Epoetin Alfa (Type: ACTIVE_COMPARATOR): As prescribed, (iv), 3 times weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Losartan and Inflammation in Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CF patients homozygous for F508del and on current treatment with Orkambi™ for at least 3 months~* Age \>12 years~* Forced expiratory volume at one second (FEV1) \>/= 40% of predicted~Exclusion Criteria:~* Female patients not willing to adhere to strict birth control (combination of two methods)~* Pregnancy~* History of intolerance to angiotensin receptor blockers (ARBs)~* Treatment with angiotensin converting enzyme (ACE) inhibitor~* NPD response to zero chloride (0Cl)/isoproterenol of \> - 6.6 mV at screening (evidence of detectable CFTR activity at baseline)~* Regular use of NSAIDs or potassium supplementation, treatment with aliskiren, on anticoagulation~* Oral corticosteroid use within 6 weeks~* Exacerbation requiring treatment within 6 weeks~* Active treatment for mycobacterial infections~* Significant hypoxemia (oxygen saturation \<90% on room air and rest or use of continuous oxygen treatment), chronic respiratory failure by history (pCO2 \> 45 mmHg), clinical evidence of cor pulmonale~* Untreated arterial hypertension (systolic blood pressure \>140 mm Hg, diastolic blood pressure \> 90 mmHg)~* Blood pressure less than 90 mm Hg systolic while standing~* Cardiac, renal (creatinine 1.5 times normal limit), hepatic (LFTs \> 3x normal upper limit), neurological, psychiatric, endocrine or neoplastic diseases that are judged to interfere with participation in study~* Known renal artery stenosis~* Concomitant airway disorders other than CF, such as allergic bronchopulmonary aspergillosis (ABPA).~* Subjects with prior thoracic surgery

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Losartan group (Type: EXPERIMENTAL): Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
- Placebo group (Type: PLACEBO_COMPARATOR): Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute wounds with substance defect after primary suture demanding further treatment or wounds not primary sutured~* wounds with osteosynthesis, bone or tendon visual regardless wound size~* postoperative infections with wound and substance defect demanding further treatment.~* fasciotomy on extremity~Exclusion Criteria:~* wound size \< 2 cm and depth \< 1 cm~* pressure ulcers, open abdomen and chronic ulcers~* patients with dementia or mental illness so severe that participation in the study is impossible~* patients non in command of the swedish language~* ongoing treatment with warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional treatment (Type: ACTIVE_COMPARATOR): None
- VAC treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: China Ovarian Cancer BRCA Testing Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Be able and willing to sign the informed consent form (ICF)~* Female aged 18 years or over~* Have histologically confirmed new diagnosis of Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian epithelial, primary peritoneal, or fallopian tube cancer made by one or more of the following:~  * standard staging laparotomy including bilateral salpingo-oophorectomy, omentectomy, and lymph node sampling and debulkingand/or~ * surgical resection and radiographic evidence consistent with Stage III or IV ovarian cancer~ * biopsy with radiographic evidence consistent with Stage III or IV ovarian cancer~* Have availability of paraffin-embedded archivedtumor tissue block (preferred) or,if a block is not possible, a minimum of twenty 5-μm unstained sections. (Tumor tissue should be archived at diagnosis. 10 slides is utilized for sBRCA testing after the enrolment. Another 10 slides is utilized for exploratory evaluation of HRR gene mutations in a retrospective way.)~* Have a diagnosis that is within 60 days of informed consent~Exclusion Criteria:~* Have a diagnosis of additional concurrent malignancies or previous diagnosis of another malignancy with current evidence of residual disease~* Have a diagnosis of other severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results and, in the judgement of the Investigator, would make the patient inappropriate for enrollment in this study~* Be currently participating in any other clinical trial for first-line treatment of ovarian cancer~* Be a patient who, in the judgement of the Investigator, would be inappropriate for enrollment in this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Physical Activity Program and Nutrition Therapeutic Education During Treatment of Head and Neck Cancer Population

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age\>18 years~* Written informed consent provided before any study specific procedures~* Consent to cooperate for clinical assessments~* Affiliation to a social security regime or beneficiary of equivalent social protection~* Performance status between 0 and 2~* Squamous cell carcinoma of oral cavity, oropharynx or hypopharynx~* Stage III - IV (T1-T4, N0-N3, M)(UICC 2002)~* Indication of radiotherapy and chemotherapy post-operative or first-line metastatic chemotherapy or in inoperable condition~* Ability to understand the nature, goal and study methodology~Exclusion Criteria:~* Prior neoadjuvant chemotherapy~* timed vital capacity\< 70%~* Presence of another severe pathology including:~* severe or chronic cardiac, pulmonary, renal and/or hepatic insufficiencies~* Cons-indication to physical activity practice, at discretion of the investigator~* Patient under guardianship~* Psychological, social, geographical, or familial reasons prohibiting physical activity and follow-up~* Any other primary tumor during the last 5 years~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- APA (Type: EXPERIMENTAL): Patient with neck cancer and accepting the physical activity program .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues